Table 2 Germline transmission rates of HDR
Male crossesFemale crosses
gRNAsdsDNA donorInjection line% (no.) founders% (no.) HDR progeny% (no.) founders% (no.) HDR progeny% germline transmission% HDR progeny per founder
S1, S2 (DNA)attPvasa-Cas922 (6/27)11 (493/4424)13 (3/23)3 (106/3233)18 (9/50)75 (36–100)
S1, S2 (DNA)attPw111822 (2/9)3 (48/1616)0 (0/9)0 (0/1400)11 (2/18)19 (11–28)
S1, S2 (DNA)attPlig40 (0/11)0 (0/2599)0 (0/17)0 (0/3066)0 (0/28)0
S1, S2 (RNA)attPvasa-Cas95 (1/21)0.1 (2/3711)0 (0/10)0 (0/862)3 (1/31)2
S1, S3 (DNA)FRTsvasa-Cas911 (1/9)1 (17/1561)14 (1/7)4 (28/716)13 (2/16)22 (12–32)
  • The indicated gRNAs were co-injected into vasa-Cas9 flies. For injections into w1118 and lig4 injections, the indicated gRNAs were co-injected with pBS-hsp70-Cas9. Injected flies were crossed to w1118 and progeny screened for DsRed-positive eyes. The percentage of crosses producing one or more transgenic progeny (founders) is indicated along with the percentage of HDR progeny. At least one DsRed-positive progeny per founder was sequenced to confirm the targeted HDR.